Haisco Pharmaceutical Group Co., Ltd.

Haisco Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical company founded in 2000 and listed on the Shenzhen Stock Exchange in January 2012. The company focuses on the development, manufacturing, and sales of new drugs, positioning itself as a high-tech enterprise with significant research and development capabilities within China's chemical pharmaceutical industry. Haisco operates a robust R&D Center that employs over 1,000 scientific researchers and is currently advancing around 50 projects across various therapeutic areas, including anesthesia, diabetes, tumors, and cardiovascular health. The company has successfully launched four innovative drugs: Ciprofol Injection, Crisugabalin Besilate Capsules, Cofrogliptin Tablets, and Enrecofen Injection. Haisco maintains a comprehensive sales network throughout China, utilizing a diversified marketing model to enhance its reach and effectiveness in the pharmaceutical market. The company is committed to increasing its R&D investments to drive the development of new generation innovative drugs.

Haisco owns a strong technical force. The scientific research work of the R&D Center involves multiple therapeutic areas such as perioperative, tumor, metabolic diseases and respiratory diseases. Currently, there are about 50 projects under development, where 26 of them are First-Class new drugs. Currently, the four innovative drugs approved for marketing by the company are Ciprofol Injection, Crisugabalin Besilate Capsules, Cofrogliptin Tablets and Enrecofen Injection, which will form the mainstay of the company's future sales revenue.